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Also, national societies of medical physicists and RTTs have 
been addressed in order to gather information regarding legal 
requirements in the different countries.  
Through the dissemination of the results from these surveys, 
and an associated literature review, the goal of this task 
group is to make radiotherapy professionals familiar with 
industrial quality management tools, and how these methods 
can be applied in our field. It is our hope that this may help 
optimising time and resources spent on quality assurance 
procedures within radiotherapy in the future. 
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Purpose/Objective: With a library-based plan-of-the-day 
(POTD) strategy, several patient-specific plans are created 
with the same dose prescription in order to account for day-
to-day anatomical variations in target shape and position. 
Currently, commercial record & verify (R&V) systems lack 
dedicated tools to efficiently and safely perform these 
treatments. The purpose of this work was to develop and 
implement a novel software tool in our R&V software 
(MOSAIQ, Elekta AB) in order to improve safety and efficiency 
in library-based POTD workflows. 
Materials and Methods: An extensive risk analysis of the 
library-based POTD procedure in our institution was 
performed to reveal potential risks in the clinical workflow 
during the treatment preparation and execution phase. Of 
major concern was excessive dose delivery. In the original 
procedure, all POTD plans were simultaneously scheduled in 
the R&V system and non-selected plans had to be removed 
manually. Furthermore, we identified deviations from the 
normal clinical workflow, such as adding plans in case the 
treatment course was started with an incomplete plan library 
or continuing with a completely renewed plan library. From 
all these analyses, logical checks on patient eligibility, dose 
administration and dose delivery were devised. These checks 
were put in a logical order in a decision tree and used to 
design a novel software tool to deal safely with all possible 
clinical situations. The tool has been developed using IQ-
scripting in MOSAIQ in close collaboration with Elekta. 
Results: The developed IQ-script is executed at the start of 
every treatment. Protocol-specific tags are attached to POTD 
plans to specify that a patient is on a POTD protocol. When 
all subsequent checks are passed, a straightforward plan 
selection dialogue is shown to the RTT. Upon confirmation of 
the selected plan, the appropriate fields are inserted in 
today's treatment session. Otherwise, a warning or error 
dialogue is displayed, and, depending on the severity of the 
violation, dose delivery is prevented or user intervention is 
required to continue treatment. For non-POTD patients, the 
script exits immediately when no tags are found. Extensive 
testing was done in MOSAIQ 2.5 by mimicking situations that 
may occur in clinical practice, including treatment 
continuation after an interrupt within a field or fraction. The 
software tool has been in clinical use since October 2014. 
Conclusions: We demonstrated the feasibily of IQ-scripting to 
extent the R&V system for improved safety and efficiency in 
library-based plan-of-the-day strategies. This tool paths the 
way to a wide-spread implementation of those strategies and 
to more advanced library-based approaches including 
dynamic plan-library updates.  
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Purpose/Objective: Correct and consistent patient 
positioning is extremely important when highly conformal 
dose distributions are delivered using VMAT. Therefore, the 
application of Statistical Process Control (SPC) may be useful 
for the quality control of patient positioning. SPC has been 
widely used as a quality management tool to monitor 
manufacturing processes in industry since the 1950’s. 
However, only a limited number of SPC applications within 
radiotherapy have been reported in literature since the first 
papers on this subject around 2000. This study investigates 
the application of SPC for the quality control of patient 
positioning during head and neck radiotherapy. 
Materials and Methods: More than 100 Head and Neck cancer 
patients treated in the last 2.5 years were included in this 
study. On average 7 CBCT scans per patient were sequentially 
registered using each of the following match structures: C1-
C3, C3-C5, C5-C7, C7-caudal, the larynx, mandible, jugular 
notch and occipital bone. This enabled quantification of the 
patient deformation during treatment by calculating the 
position of each structure relative to C1-C3. So-called 
‘Individual Values’, ‘Moving Range’, and ‘Exponentially 
Weighted Moving Average’ SPC charts were used to 
retrospectively analyse improvements in patient deformation 
over time which were observed after the instigation of a 
multi-disciplinary working group. In addition, SPC charts were 
used to monitor deformation during the treatment of the 
subsequent patient cohort, as well as for monitoring the 
positioning accuracy of individual patients. 
Results: 
 
 
SPC charts showed that a significant and consistent 
improvement in patient positioning has been achieved since 
the instigation of the multi-disciplinary working group. Fig.1 
shows how the magnitude and the variation of the average 
systematic 3D-deformation vector decreased from 3.0 ± 0.9 
mm (1 S.D.) in 2011 to 2.2 ± 0.4 mm (1 S.D.) in the first 3 
months of 2014. Further analysis of the data revealed that 
the application of a different type of head rest, and re-
training of staff members in mask-making were key factors in 
improving patient positioning. Continued monitoring of the 
results from April 2014 onwards showed that the patient 
deformation was well within the process limits for most 
patients, which indicated that the improvements are 
consistent. However, the results for two patients exhibited 
larger deviations that could be attributed to exceptional 
circumstances for these two patients. These observations 
S164                                                                                                                                         3rd ESTRO Forum 2015 
 
highlighted the need to monitor individual patient 
deformation during the treatment course. This application of 
SPC showed that EWMA charts can efficiently detect small 
shifts early on in the treatment, which would enable a timely 
decision for plan adaptation if necessary. 
Conclusions: SPC is a very effective tool for reviewing and 
monitoring the accuracy of patient positioning. 
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Experimental studies on the retreatment tolerance of 
previously irradiated tissues have generally been performed 
in the 1980’s and 90’s, and were mostly limited in scope. 
Generally, the retreatment tolerance of different tissues and 
organs differ for early and late responding tissues. 
Early responding tissues are characterized by rapid 
proliferation and a clearly defined stem cell compartment 
(epidermis, mucosal lining of GI-tract) with the timing of 
response related to the turnover times of stem cells.  Except 
after very severe early reactions these tissues show a 
complete restauration of tolerance. 
Late tissue reactions in slowly or non-proliferating tissues 
show a much more limited long term recovery which is also 
dependent on the dose of the initial treatment. An example 
of such a tissue is the lung, contrasting with the kidney that 
does not show any recovery at all.  
A paradoxical exception is the central nervous system, which 
based on its proliferation characteristics is not expected to 
show any significant recovery. However, extensive studies in 
several institutions have shown that the spinal cord shows 
almost complete recovery when the initial dose is 
approximately 50-75% of full tolerance.   
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Purpose: Despite aggressive multimodality treatment 
protocols used in first-line treatment, a significant proportion 
of patients with different cancer develop locoregional 
recurrences in previously irradiated area, typically during the 
first years of follow-up. Compared to salvage external-beam 
radiation therapy the salvage interstitial brachytherapy offers 
clearly better possibility to give high doses without inevitably 
leading to high complication rates.  
Methods and results: The author analyses and review the 
role of salvage brachytherapy in previously irradiated 
patients with breast cancer, prostate cancer, head-and-neck 
malignancies, Gyn tumors, cancer of anorectal region and 
other tumors.  
An overview of selected results of modern image-guided 
salvage brachytherapy will be given. The analysis makes 
evident, that re-irradiation with doses in the range of 55-60 
Gy (after previous irradiation up to doses of 60-70 Gy) 
represents very narrow tightrope walk between realistic 
tumor control probability and an unacceptable incidence of 
serious side effects. However, a reasonable number of these 
patients, if selected carefully, may have a chance for long-
term disease control. The observed local control rates of 
salvage brachytherapy for previously irradiated recurrent 
head and neck cancer vary very widely between 16% and 86% 
after 2 to 5 years, for previously irradiated recurrent 
prostate cancer between 30% and 90%, for previously 
irradiated recurrent breast cancer about 95%, et cetera. The 
salvage external beam radiation therapy is in these 
indications mostly not possible and compared with the results 
of salvage surgery the salvage brachytherapy seems to offer 
lower toxicities in all indications.  
Conclusion: Salvage interstitial brachytherapy in selected 
patients with locoregional recurrences in previously 
irradiated area is for a whole range of tumors proven, safe 
and effective treatment method with very good long-term 
data and with minimal toxicity.  
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Purpose: Re-irradiation of the recurrences in the areas of 
head and neck (h/n) and upper respiratory tract should 
always be considered as a risky treatment. These cancers 
quite often need to be radiate the second time because of 
their relapse and clinical advancement in the primary 
examination. High dose rate brachytherapy (HDR-BT) is very 
useful in short time tumor dose delivering when external 
beam radiotherapy (EBRT) is not possible to depot once more 
after previous treatment failure. Pulsed dose rate 
brachytherapy (PDR-BT) is safe but longer method of salvages 
and according to differences in recovery times allows better 
sparing healthy tissue during second radiation treatment. The 
aim of this work was to analyze the results and complications 
rates of another radiation treatment patients with recurrent 
tumors in head and neck and upper respiratory tract. 
Material and methods: 47 patients with h/n and 22 with 
larynx/trachea (l/t) recurrent cancers were enrolled  to the 
study. The mean time of the recurrence after diagnosing of 
the disease and first treatment was 9,7 months. 50 patients 
were treated by the HDR brachytherapy (5 doses of 4 Gy) and 
19 by PDR-BT with total dose ranged between 20-40 Gy (0,8 
Gy per pulse) with one or two stage treatments (respectively 
9 and 4 doses). HDR-BT and PDR-BT were performed with a 
remote afterloading microSelectron unit (192Ir source) after 
planning procedure (Oncentra system). Mean age of patients 
undergoing observation was 50,1 years. 
In three l/t patients, BT procedures were performed in 
combination with simultaneous chemotherapy. In 16 patients 
cytoreduction of the tumor preceded interstitial, surgical 
catheter placement. Local control, survival rates and 
tolerance of the treatment were discussed. 
Results: The remission after 1,3,6 months after treatment 
and early complication were assessed. In 15% patients 
complete remission (CR), in 65,9% partial remission (PR) and 
10,6 % no response for brachytherapy (NR) were stated; in 
the other (8,5%) patients there were progression (P) of the 
tumor. Percentages of remission after 3 and 6 months were: 
CR – 10,6 % and 6,4%, PR – 53,2% and 36,2%, NR and P – 36,2% 
and 57,4%, respectively. For the l/t group complete and 
partial remissions in 6 months treatment time were achieved 
in 20% patients, survival rate 24 months after BT were 
estimated for 22%. Progression of the disease was noted in 
60% of cases.  The most common side effect was superficial 
